Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart, Inc. develops oral recombinant pill vaccines based on a proprietary delivery platform. The clinical-stage biotechnology company’s programs include vaccine candidates for coronavirus, norovirus and influenza, as well as a therapeutic human papillomavirus vaccine as its first immune-oncology indication. Its pill-based vaccines are designed for oral administration, storage and shipping without refrigeration, and avoidance of needle-stick risk.
Vaxart news centers on clinical data and scientific publications, business updates, financial results, financing arrangements, collaborations, intellectual property around adenovirus and TLR3 agonist oral vaccination technology, and governance changes as the company advances its oral vaccine pipeline.
Vaxart announced promising preclinical results for its oral COVID-19 vaccine candidates, which demonstrated robust antibody responses in tested animals. The company plans to initiate a Phase 1 clinical study in the second half of 2020. Financially, Vaxart reported a net loss of $1.3 million for Q1 2020, identical to Q1 2019, but with a reduced net loss per share of $0.02 compared to $0.18 in the prior year. Cash equivalents increased to $29.9 million due to a successful stock offering, despite a revenue decline to $2.9 million from $5.4 million in Q1 2019.